| Identification | Back Directory | [Name]
Rifalazil | [CAS]
129791-92-0 | [Synonyms]
KRM 1648
RIFALAZIL
Rifalazil USP/EP/BP
3'-Hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin
1-Deoxy-1'-dehydro-1-oxo-3'-hydroxy-5'-[4-(2-methylpropyl)piperazino]rifamycin VIII
5,12-Dihydroxy-2,4-dimethyl-10-[4-(2-methyl-propyl)-l-piperazinyl]-2,7-[oxy(5-acetoxy-7,9-dihydroxy-3-methoxy-4,6,8,10,14-pentamethyl-15-oxo-l,ll,13-pentadecatriene-l,15-diyl)imino]-6H-benzofuro[4,5-a]phenoxazine-l(2H),6-dione | [Molecular Formula]
C51H64N4O13 | [MDL Number]
MFCD00871530 | [MOL File]
129791-92-0.mol | [Molecular Weight]
941.07 |
| Chemical Properties | Back Directory | [Melting point ]
195-200° (dec) | [Boiling point ]
1065.6±65.0 °C(Predicted) | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, away from moisture | [solubility ]
DMSO: 8.33 mg/mL (8.85 mM) | [form ]
Solid | [pka]
4.28±0.70(Predicted) | [color ]
Blue to dark blue |
| Hazard Information | Back Directory | [Uses]
Antibacterial (antimycobacterial). | [Definition]
ChEBI: Rifalazil is a phenoxazine. | [in vivo]
Rifalazil (oral gavage; 20, 25, and 150 mg/kg; 6-8 weeks) combines with isoniazid (INH) for 6 weeks or greater significantly reduced the number of mice per group in which M. tuberculosis is detected in both spleens and lungs compared to the reductions for the early and late controls. And the addition of Pyrazinamide (PZA) does not significantly improve RLZ-INH therapy at any time point[2]. | Animal Model: | Female CD-1 mice infected with 5.2 × 107?viable mycobacteria[2] | | Dosage: | 20, 25, and 150 mg/kg; 6-8 weeks | | Administration: | Oral gavage | | Result: | Combined with isoniazid (INH) showed its potential for short-course treatment of?Mycobacterium tuberculosis?infection. |
| [storage]
4°C, away from moisture |
|
| Company Name: |
TOSUN PHARM
|
| Telephone: |
020-66392521-118 18922260391 |
| Website: |
www.toref.cn/ |
|